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Abstract: As of 21
st
 century, cancer is arguably the most complex and challenging disease known to mankind and an 
inevitable public health concern of this millennium. Nanotechnology, suitably amalgamated with cancer research, has 
ushered an era of highly personalized and safer medicines which can improve cancer diagnosis and therapy. A wide 
variety of nanomedicines are currently under investigation, including polymeric/non-polymeric nanoparticles, dendrimers, 
quantum dots, carbon nanotubes, lipid- and micelle-based nanoparticles. The bases of these nanomedicines in reducing 
toxicity associated with cancer therapy are their ability to carry a large payload and multivalent-ligand targeting. This 
imparts specificity for targeting the tissues as well as bypass resistance mechanisms. The major hurdles on these future 
medicines are potential toxicity of nanoparticles, which imposes the need of extensive regulatory evaluation before 
nanomedicines could be utilized as cancer therapeutics. This review highlights nanopharmaceuticals that have been 
investigated in oncology for various applications (diagnosis, therapeutic delivery and theranostics). It also discusses the 
effects of nano-sized materials on tissues/organ functions, the possibility of overcoming multi-drug resistance by using 
nanomedicines and their current clinical status.  
Keywords: Cancer nanomedicine, multi-drug resistance, nanotechnology, nanotoxicity, regulatory, theranostics. 
INTRODUCTION 
The practice of cancer therapy has changed considerably 
in the past decades. Curative treatments have been achieved 
for a number of fatal malignancies such as testicular cancer, 
lymphomas and leukemias. However, there are still 
numerous constraints associated with the use of conventional 
chemotherapeutic agents. Although some of the newer 
agents indirectly target the survival of tumor cells, viz. 
bevacizumab (Avastin) inhibits tumor angiogenesis [1], and 
ipilimumab is an immunotherapeutic antibodiy [2], the 
majority of them act by directly killing the cells in a more or 
less specific manner. Such agents are associated with dose-
limiting side-effects and anticancer drug resistance, since 
complete elimination of malignant cells is often not possible 
using therapeutic doses. To overcome these problems, 
various approaches are being developed that use nanocarriers 
for targeting tumor site via passive or active means [1, 2]. 
According to the US Food and Drug Administration (FDA), 
nanotechnology product refers to products that are at least 
one dimension in the length scale between 1-100 nm and 
display functional behavior in relation to their nanosized 
properties [3]. Tailor-made nanomaterials can be useful for  
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reducing multi-drug resistance, evading blood-brain barrier 
(BBB), and diagnosis and imaging of cancer [3]. Even 
though the research in pharmaceutical nanotechnology is in a 
very active stage, approved nanomedicines in the clinical 
practice is very low. However, it is encouraging to observe 
that there are many nanoformulations that are either 
approved, or in different phases of clinical trials [4]. The 
commercially available nanomedicines that are clinically 
employed in cancer treatment are Doxil
®
/Caelyx
® 
and 
Abraxane
®
.
 
Doxil
® 
is a liposomal formulation of doxorubicin, 
which is approved for treatment of Kaposi’s sarcoma, 
refractory breast and ovarian cancer. Abraxane
®
 is an 
albumin-based formulation of paclitaxel that has been 
approved for the treatment of metastatic breast cancer. 
Despite the progress of some nanomedicines in clinical 
practice, there are still issues related to their tissues/organ 
biodistribution, toxicity, environmental and regulatory 
aspects. This manuscript reviews mechanisms of action, 
toxicity, and regulatory aspects, recent advances, and future 
prospects of different nano-carriers developed as anticancer 
therapeutic and diagnostic agents (theranostics).  
TARGETING STRATEGIES AND ROLE OF 
NANOMEDICINE 
Tumor blood vessels possess distinctive pathophysiological 
characteristics that are not observed in normal blood vessels, 
viz. a relatively high proportion of proliferating endothelial 
cells, increased tortuosity, pericyte deficiency and aberrant 
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basement membrane. Moreover, tumors also feature a 
decreased lymphatic drainage resulting in increased retention 
of extravasated macromolecules. This phenomenon is 
described as “enhanced permeation and retention (EPR) 
effect” [5-7], which is often proposed as the underlying 
mechanism for the accumulation of nanocarriers in tumors, 
and forms the basis of passive targeting. Alternatively, 
nanocarriers can accumulate in tumors by active targeting 
strategy, which involves binding of nanomaterials to surface-
exposed receptors on tumor cells or tumor blood vessels. 
Passive and active targeting will be discussed in more detail 
in the later section. Therefore, irregular tumor vasculature 
and impaired lymphatic drainage create high interstitial fluid 
pressure with an extremely hydrophilic environment [6], 
which may limit the distribution of drugs to solid tumors. 
Likewise, the presence of extracellular matrix of the tumor, 
fibrillar collagen, and necrotic non-supporting regions serve 
as barriers for the effective delivery of drugs [6-9]. It has 
been proposed that antiangiogenic agents may normalize an 
efficient blood flow to tumors, which will decrease the 
hypertensive interstitial condition, thereby improving the 
delivery of chemotherapeutics [10]. Drugs that have been 
shown to successfully normalize the tumor vasculature 
include anti-VEGF antibody bevacizumab [11].  
Passive Targeting 
Fast growing vascularization, leakiness and defective 
lymphatic drainage all contribute to the retention of 
macromolecules and nanoparticles in tumors, which is the 
rationale for EPR-based drug targeting. Studies with 
liposomes and other nanoparticles have indicated that the 
cut-off size of the pores in tumor vessels is as large as 200 
nm–1.2 m [12-15]. In fact, it is now established that 
nanoparticles with a size range of 10–100 nm can 
accumulate in tumor tissue via EPR effect [12-13]. Both, the 
size of nanoparticles and their surface properties must be 
tailored appropriately to avoid phagocytosis by the RES 
(reticuloendothelial system). Hydrophilic surface coating of 
nanoparticulate systems by PEG, poloxamers, poloxamine, 
polysachharide and branched/block amphiphilic co-polymers 
have been successfully applied for this purpose [12-14].  
Active Targeting 
Active targeting approach is based on the interaction of a 
ligand-equipped nanocarrier with surface-exposed receptors 
on target cells, which will help in their accumulation in 
tumor and, more importantly, will facilitate their intracellular 
accumulation via receptor-mediated endocytosis [15-17]. 
Most cancerous cells have one or more types of over-
expressed molecular targets which may serve as the site for 
active targeting through nanomedicine. Endocytosed 
particles are transported to endosomes and subsequently to 
lysosomes, where further processing of the particles and 
release of drug(s) is affected by the presence of lysosomal 
enzymes and low pH of this intracellular compartment. 
Active targeting mechanisms provide an alternative means to 
combat multi-drug resistance (MDR) because resistance 
inducing proteins such as P-glycoprotein (P-gp) cannot 
pump out nanoparticle-associated drug or drug-polymer 
conjugates that have entered the cell via the endocytic 
mechanism [15-21].  
Folate Receptor–Based Targeting 
Folic acid, an oxidized form of folate, is a vitamin 
required for one-carbon transfer reactions and is essential for 
the de novo biosynthesis of DNA and several nucleotide 
bases [22]. Folate transport across plasma membrane in 
normal cells is carried out either by folate carrier or by folate 
receptor [23].
 
Folate receptor is a highly selective tumor 
marker, which is overexpressed (100- to 300-times higher 
than in normal tissue) in many human cancer cells such as 
brain, kidney, breast and lung [24]. Therefore, folate-based 
targeting ligands find potential applications in the diagnosis 
and delivery of chemotherapeutic agents [23]. Their high 
receptor affinity and restricted interaction with normal 
tissues facilitate the delivery of therapeutic agents selectively 
to the target site [25-28].  
Monoclonal Antibody–Based Targeting 
Monoclonal antibodies (Mabs) are antibodies obtained 
from a single clone of a parent immune cell. These are 
immunoglobulins based on complex proteins, which contain 
mainly two regions; the antigen-binding fragment (Fab) and 
complement fixing fragment (Fc), which are responsible for 
specific antigen binding and fixing complement for in-vivo 
biological response [29]. Primary tumors as well as 
metastatic tumors generally over-express certain antigens on 
their surfaces (like HER2 in breast cancer, epidermal growth 
factor receptor in lymphoma, etc.). Mabs specific to 
particular antigens provide an ideal platform for conjugated 
drug targeting [30]. Current research is being focused on the 
development of chimeric and fully humanized derivatives of 
such targeting Mabs to decrease their immunogenicity [31]. 
PLGA immuno-nanoparticles conjugated with Mabs directed 
to breast cancer cytokeratins interacted specifically with 
MCF-10A neoT [32]. Steinhauser and co-workers suggested 
trastuzumab-modified nanoparticles for the treatment of 
HER2-over-expressing breast cancer cells [33]. In 2004, 
Gemtuzumab-ozogamicin (Mylotarg), which is targeted to 
the cell-surface receptor CD33, was approved by FDA for 
the treatment of acute myelogenous leukemia (AML) [34]. 
This conjugate was however withdrawn from the market in 
2010 due to fatal toxicity in phase-3 clinical trials.  
Beside this, several other drug-antibody conjugates have 
been developed. Some of them are already approved while 
others are in different phases of clinical trials. From this 
category, Brentuximab vedotin that binds to CD30, a tumor-
specific marker of the TNF-receptor superfamily, has 
recently been approved for the treatment of Hodgkin and 
systemic anaplastic large cell lymphomas [35, 36]. Additionally, 
Inotuzumab ozogamicin (target: CD22) and Trastuzumab 
emtansine (target: HER2) have shown pronounced clinical 
activity in phase 3 clinical trials for non-Hodgkin lymphoma, 
acute lymphocytic leukemia and metastatic breast cancer 
[35, 37]. 
CD95 Targeting 
CD95 is a tumor necrosis factor (TNF) receptor that 
prompts cell apoptosis of peripheral T-cells upon oligo- 
merization [38]. CD95-mediated immunological destruction 
of liver tissue (in hepatitis) and the CD95 death system’s role 
in killing infected hepatocytes is well established.  
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McCarron et al. reported a novel immuno-nanoparticle 
against colorectal tumor cells. Nanoparticles were 
peripherally coated with antibodies directed to CD95 and 
loaded with camptothecin. Effective internalization was 
confirmed by fluorescence visualization studies in HCT116 
cell line. Similarly, they developed camptothecin nano- 
particles without anti-CD95 Mab, which showed poor 
internalization kinetics [39].  
Transmembrane Tyrosine Kinase Receptor Targeting 
Huh et al. successfully worked on metallic nanoparticles 
tagged with trastuzumab leading to localized intratumoral 
accumulation in-vivo [40]. Akira et al. encapsulated metallic 
nanoparticles (MNPs) in anti-HER2 immunoliposomes and 
used these antibody-directed nanoparticles for hyperthermia 
therapy [41]. Similarly, gold nanoshells were developed for 
targeting and photothermal therapy of HER2 over-expressing 
ovarian cancer OVCAR3 cells. OVCAR3 cells that had 
internalized the metallic nanoparticles were irradiated with 
near infra-red (NIR) radiation leading to selective destruction 
of cancer cells through photothermal ablation [42]. Parallel 
to this theme, Day et al. developed gold-gold-sulphide 
nanoparticles that were used in photo-ablation therapy. 
These nanoparticles could be imaged via multiphoton 
microscopy and could induce thermal damage via 
hyperthermic NIR [43]. 
Aptamer-Based Targeting 
Identification of target proteins having a clear link with 
human oncologic disorders offers a powerful tool for the 
development of relevant aptamer ligands. Aptamers, a class 
of macromolecules containing single-stranded RNA or DNA 
(ssRNA or ssDNA), can be selected from random pools, 
based on their antigen binding affinity [44, 45]. A group of 
researchers have hypothesized an automated selection 
process (termed as “systematic evolution of ligands”) by 
exponential enrichment for rapid isolation of RNA ligands 
and aptamers [46]. Aptamers possess many favorable 
characteristics such as ease of chemical isolation, selective 
binding affinity, small physical size, and lack of 
immunogenicity, which make them useful as homing ligands 
in nanomedicine-based cancer therapy [47-50]. Furthermore, 
aptamers can be surface-modified with various functional 
groups to facilitate their conjugation with nanomaterials, 
which could be exploited for their selective targeting in the 
diagnosis and therapy of cancer [46, 48, 49]. Nanoparticles 
(PLGA–block-PEG copolymer) along with A10 aptamer 
bioconjugates have been targeted to prostate-specific 
membrane antigen (PSMA), which is a transmembrane 
protein responsible for prostate cancer [49]. In another study, 
a marked reduction in tumor size was observed over a period 
of 109 days after a single intra-tumoral injection of aptamer-
decorated nanoparticles [50]. Their specific binding affinity 
with PSMA cells was further confirmed by in-vivo cellular 
imaging techniques using an aptamer conjugated to 
luminescent CdSe and CdTe nanocrystals, which were found 
to be more concentrated in prostate tumor cells. Research is 
being directed for the development of aptamers that can bind 
selectively to vascular endothelial growth factor (VEGF), a 
protein involved in angiogenesis. They would especially be 
useful in the treatment of age-related macular degeneration 
[51].  
Integrin-Based Targeting 
Integrins were originally characterized as a family of cell 
adhesion receptors that bind to extracellular matrix and cell-
surface ligands. The role of cell-surface integrin is to 
transmit and detect changes from the extracellular matrix to 
intracellular signaling, and thus regulate tumor growth, 
angiogenesis, proliferation, apoptosis and metastasis [52]. 
Several integrins play a key role in promoting tumor 
angiogenesis and metastasis. Within the family, v3 integrin 
adhesion receptor is the main marker of angiogenic blood 
vessels in the mammalian system, and is over-expressed on 
growth factor–activated endothelial cells. A synthetic 
peptide bearing Arg-Gly-Asp sequence specifically binds to 
the v3 integrin and can be used to selectively target 
angiogenic blood vessels [53].  
Drug Like Peptides: Vasoactive Intestinal Peptide 
Vasoactive intestinal peptide (VIP) is a 28-amino acid 
neuropeptide of the glucagon-secretin category that is 
distributed widely in both the central and peripheral nervous 
systems. VIP receptors are five-times more abundant in 
breast cancer cells than in normal breast cells. Additionally, 
VIP is synthesized locally within the eye and takes part in 
immunological homeostasis of the ocular microenvironment. 
However, its potential therapeutic applications are restricted 
because of its failure to cross the blood-brain barrier (BBB), 
rapid elimination and degradation (half-life <1 min) after i.v. 
administration. Therefore, various formulation-based 
approaches have been explored to protect its degradation and 
make it available in the intact form, mostly via the nose-to-
brain pathway. For brain delivery, a VIP analogue was 
conjugated to OX26 monoclonal murine antibody and 
directed against the rat transferrin receptors [54]. Embedding 
VIP into wheat germ agglutinin–coated PEG-PLA or 
protamine-oligonucleotide nanoparticles enhanced their 
transport to the brain after intranasal administration [55]. 
The VIP receptor, in addition to HER-2 and estrogen 
receptors, is present in high density and considered as the 
biomarker or molecular target for breast cancer. The 
overexpression of VIP receptors is increasingly being used to 
develop new drugs for the treatment of cancer patients. 
Targeting PEGylated liposomes, which contain radionuclides 
to VIP receptors of tumor, resulted in an enhanced passive 
and active breast cancer inhibition in rats [56].  
Luteinizing Hormone-Releasing Hormone (LHRH) 
Targeting 
Luteinizing hormone-releasing hormone (LHRH) is 
another targeting moiety. The LHRH receptor is barely 
present on the surface of most healthy human cells, but is 
over-expressed in ovarian and some other cancer cells [57, 
58]. Dharap et al. recently developed the LHRH–PEG–
camptothecin targeted anticancer drug delivery system, 
wherein LHRH targets the corresponding receptors in  
cancer cells, PEG prolongs the blood circulation time, and 
camptothecin functions as the anticancer drug [58]. The 
targeted conjugate exhibited significantly higher cytotoxicity 
against cancer cells than the non-targeted PEG–camptothecin 
conjugate or the free drug in vivo, indicating the validity of 
actively targeted nanoparticles for anticancer therapy. The 
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list of various targeting ligands and their respective targets 
are given in Table 1. 
CLASSIFICATION OF NANOCARRIERS IN 
ONCOLOGY 
Advancement and growing interest in nanotechnology-
based drug delivery systems and imaging agents have 
dramatically increased their market potential. The market of 
nanopharmaceuticals is growing by 17% and expected to 
have a $53 billion market in 2014. Hence, a steady 
succession of nanomedicines is anticipated to seek 
regulatory approvals and subsequent access to human use. 
Nanomedicines have several features that make them 
especially adept at carrying anticancer compounds to tumors. 
First, they are large enough to avoid rapid elimination 
through the kidney, yet they are small enough that they may 
penetrate the leaky vasculature of the tumor tissues and get 
trapped because of the EPR effect; nanoparticles only show 
this EPR effect in tumors or inflamed tissues that also have a 
leaky vasculature, while they avoid normal tissues to a large 
extent since they cannot penetrate the intact endothelial 
barrier. Second, nanomedicines can enter a cell by endocytosis 
very efficiently especially when decorated with targeting 
ligands. Furthermore, after intracellular accumulation, 
nanocarriers protect the particle’s payload from being 
expelled by cellular pumps that otherwise are responsible for 
drug resistance. Nanoparticles are useful carriers especially 
for drugs that operate intracellularly such as interference 
RNA. Another attractive feature of nanoparticulate systems 
is that they can incorporate multiple drugs, making 
combination therapy possible on a single platform. On the 
basis of application in oncology, nanopharmaceuticals may 
be classified as therapeutics, diagnostics or theranostics (i.e. 
combination of both). The developed nanocarriers for 
medicines are illustrated in Fig. (1). Diverse classes of 
nanomedicines have been developed till now and they have 
their own advantages and disadvantage as drug carriers 
(Table 2).  
Liposomes 
Liposomes are a family of microscopic, concentric 
lamellar structures enclosing an aqueous volume by a 
membranous lipid bilayer. They are formed by blending 
natural or synthetic phospholipids, cholesterol and 
tocopheryl acetate, and their subsequent hydration in the 
aqueous media. Liposomes have been studied and evaluated 
extensively for the spatial and temporal delivery of 
anticancer agents. First liposomal product approved by FDA 
is Doxil
®
 in 1995 for the treatment of Kaposi’s sarcoma, 
refractory breast and ovarian cancer. Liposomes qualify as 
suitable candidates for delivering drugs in oncological 
disorders owing to their straightforward formulation 
methodology, as well as their versatility in entrapping both 
hydrophilic and lipophilic drugs [59-61]. PEGylated or 
stealth liposomes (long circulating) exhibit remarkable 
inhibition of the rapid uptake by the RES cells, leading to an 
improved extravasation profile and enhanced intratumoral 
localization. Conjugation of a targeting ligand to liposomes 
can take the tumor targeting approach to a higher level. A 
study conducted pertaining to the uptake of folate-PEG-
Table 1. Different targeting ligands, specific targets and their application in drug targeting in different cancers. 
Targeting Ligands Specific Targets Location Targeting Application in Oncology References 
NGR peptide Aminopeptidase N Cell surface  Vasculature in solid tumors [150] 
Ab & Ab-derived peptides Aminopeptidase P Caveoli Lung cancer [151] 
Antibody (Rituxan, 
Zevalin) 
B-lymphocyte antigen 
CD20 
Cell membrane surface B cell lymphomas [152, 153] 
Ab (Erbitux) aptamers EGF receptor (ErbB1) Cell membrane surface & lipid rafts Metastatic colorectal cancer [154] 
Ab, Ab-derived peptide Endoglin Cell membrane surface and caveoli Vasculature in solid tumors [155] 
Peptides, Ab, Ab-derived 
peptides 
ICAM-1 Cell membrane surface Vasculature in solid tumors [156] 
Ab (Avastin), peptides VEGF receptor Cell membrane surface Vasculature in solid tumors [157] 
Ab & Ab-derived peptides PECAM-1  Cell membrane surface lymphoid cancers [158] 
Ab aptamers MUC1  Cell membrane surface Breast & bladder cancer [159] 
Albumin & Ab gp60 Caveoli and Cell membrane surface Vascular targeting in malignant 
liver cancer  
[160] 
Trastuzumab (Herceptin), 
pertuzumab Ab, tyrosine 
kinase inhibitors  
EGF (ErbB) receptor 
(ErbB1) and EphA2 
receptor 
Cell membrane surface and lipid 
rafts 
Breast, prostate cancer, and 
Metastatic colorectal cancer 
[161] 
Ab, Ab-derived peptides, 
aptamers 
insulin-like growth 
factor receptor (IGF-1R) 
Caveoli and Cell membrane surface Lungs, pancreas and breast cancer [162, 163] 
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liposomal doxorubicin by KB cells (a cell line derived from 
human carcinoma of nasopharynx) showed 45-fold higher 
uptake of folate-targeted liposomes than of liposomal 
doxorubicin and 1.6-fold higher uptake versus free doxorubicin, 
while cytotoxicity was 86 and 2.7 times higher, respectively 
[62]. Opsonisation of plasma proteins to nanocarriers greatly 
enhances their clearance. To diminish this, albumin was 
conjugated to PEGylated doxorubicin liposomes [63]. The 
disposition of this type of nanoparticulate doxorubicin to the 
heart was significantly smaller than that of free drug, and on 
the other hand tumor accumulation of albumin-conjugated 
PEGylated liposomes was higher than the PEGylated 
liposomes. Liposomes can also be used to overcome the 
specific resistance mechanisms such as P-gp mediated drug 
efflux, and targeting drugs to tumor tissue and cells, leading 
to enhanced bioavailability at the site of action to the 
resistant tumors safely and effectively [64]. Currently, 
liposomal anthracyclines have achieved clinical use in cancer 
treatment by eliciting enhanced encapsulation of drug in a 
stable, non-reactive carrier, providing potential benefits in 
case of resistant tumors.  
Niosomes 
Nonionic surfactant-based vesicles (NSVs) are now one 
of the most widely studied alternatives to liposomes, 
resulting from the self-assembly of hydrated surfactants 
monomers. Surfactants can be employed as useful surrogates 
to phospholipids in the fabrication of vesicular systems [65, 
66], and have some advantages over liposomes like 
avoidance of superfluous use of phospholipid (vulnerable to 
oxidative degradation) thereby boosting formulation 
stability, and drastic reduction in production cost. The 
rationale behind using niosomes in anticancer therapy is to 
prolong the circulation of entrapped drug, altering its organ 
distribution and metabolic stability, as well as to reduce 
drug-induced toxic effects to extra-tumorous tissues. Like 
liposome, PEGylation and surface modification for enhanced 
tumor targeting is also possible. Lately, it has been shown 
that efficient tumor targeting of hydroxycamptothecin-
loaded pegylated niosomes is possible when modified with 
transferrin [67].  
Polymeric Micelles 
The promising potential of polymeric micelles (PMs) as 
effective drug delivery carriers in anticancer therapy has 
been a topic of discussion since decades. The major 
breakthrough was witnessed in the early 1990s by Kataoka’s 
group, who developed doxorubicin-conjugated block co-
polymer micelles [68, 69]. Since then, a large number of 
modified pendant polymeric micelles have been used for the 
delivery of chemotherapeutic agents in pre-clinical and 
clinical studies. A polymeric micelle essentially consists of 
an inner hydrophobic core (which is the part of block 
copolymer) and encapsulates a hydrophobic/poorly-water 
soluble drug, while the outer shell or the corona is composed 
of the hydrophilic part of the block copolymer. Some 
inherent properties of PMs which make them an obvious 
choice for carriers of anticancer drugs are: (1) size in nano 
range; (2) stability in plasma; (3) in vivo longevity owing to 
hydrophilic corona as observed in PEGylated (stealth) 
liposomes; and (4) EPR effect by virtue of the pathological 
characteristics of the tumor cells, is observed allowing 
passive targeting to the tumor cells [70]. The corona serves 
the dual purpose of stabilizing the PMs against recognition 
by RES cells and targeting the drugs by attaching specific 
ligands recognizing the tumor sites. Drug release can be 
coordinated and regulated by appropriate application of heat 
or ultrasound, or other external suitable stimuli. Thus, it can 
be conveniently accepted that PMs have the potential of 
active as well as passive targeting to the tumor tissues. 
 
Fig. (1). Diagrammatic illustration of different nanomedicines used in oncology. 
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Tumor angiogenesis and tumor cell targeting of PMs is a 
prospective application [71].  
Polymeric Nanoparticles 
Encapsulation, dissolution, entrapment of drug in 
nanosized particles or their attachment to a polymeric matrix 
gives rise to polymeric nanoparticles (NPs). A plethora of 
well-studied biodegradable polymers like PLA, PLGA, Poly-
-caprolactone, etc., are used to fabricate polymeric NPs, 
maximizing tissue compatibility and minimizing toxicity due 
to their biocompatibility and biodegradability. Alternatively, 
synthetic polymeric agents can also be used to formulate 
NPs and the accompanied advantages include increased 
biological half-life, reduced uptake by the RES cells and 
improved targeting to tumor cells. Mu and Feng synthesized 
PLGA NPs containing the drug Paclitaxel (PTX) (Taxol
®
) 
for solubility enhancement [72]. Gryparis and co-workers 
observed the in vitro anticancer activity of cisplatin-loaded 
PLGA-mPEG NPs on human prostate cancer LNCaP cells. It 
was found that as the PLGA/PEG ratio in PLGA-mPEG co-
polymer increased, the cytotoxicity also increased. This 
effect was observed primarily due to increased uptake by 
cells with the increasing ratio. Furthermore, it was also 
concluded that the in vitro activity of cisplatin was 
comparable to free cisplatin [73]. Li et al. prepared 
multifunctional pluronic/polyethylenimine NPs conjugated 
with folic acid (as folate) to their surface to improve 
targeting to tumor cells. They concluded that the surface-
modified PTX nanoparticles showed sustained release profile 
in contrast to PTX solution [74]. Additionally, the in vitro 
anticancer activity was also enhanced considerably as 
compared to free drug, and folate conjugated nanoparticles 
demonstrated excellent cytotoxic action. In a similar 
experiment conducted by Mo and Lim, PTX-loaded PLGA 
NPs were conjugated with wheat-germ agglutinin (WIT-NP) 
which showed superior cytotoxicity towards A549 and 
H1299 cell lines as compared to conventional PTX 
formulations (as measured by IC-50 doses). This superiority 
was attributed to a more efficient and complete intracellular 
Table 2. Common preparation methods, advantages and limitations of different nanocarriers in anticancer drug delivery. 
Nanomedicines General Preparation Technique Advantages Limitations 
Polymeric 
nanoparticles 
In-situ polymerization, nanoprecipitation, 
supercritical fluid technology, gelification, 
emulsion-solvent evaporation, Interfacial 
polymerization of monomers or phase 
inversion process with emulsions of polymers 
Multiple drug loading, Controlled release 
can be achieved for even more than 
1month by tailoring the mechanical 
properties and selection of polymer 
Stability and re-dispensability not 
always acceptable, presence of 
residual solvents, sometime brust 
release  
Solid lipid NPs Ultrasonication/high speed homogenization, 
SLN preparation by using supercritical fluid, 
High-pressure homogenization, dilution of 
microemulsions or solvent removal from oil-
in-water emulsions, solvent diffusion 
technique and freezing of an emulsion of 
lipids heated above melting point of lipids 
Established Biocompatible, Flexibility of 
size and surface manipulation, lower 
toxicity vs non-liposomal formulation, 
Feasibilities of carrying both lipophilic and 
hydrophilic drugs, Water based technology 
(avoid organic solvents), Easier to validate 
and gain regulatory approval  
Poor drug loading capacity, drug 
expulsion after polymeric transition 
during storage and relatively high 
water content of the dispersions, 
Poor batch to batch reproducibility 
Sterilization difficulties, Release of 
drug not always well controlled 
Liposomes and 
Niosomes 
Film hydration method, Reserves Phase 
Evaporation Method, Freeze-Thaw Method, 
Extrusion, Solvent Injection Methods and 
Sanitation Method 
Liposome particularly made up of natural 
lipids, Encapsulate both hydrophobic and 
hydrophilic drugs, surface 
functionalization is easy, Lower toxicity 
particularly in case of case of liposome 
Fair stability Poor batch-to-batch 
reproducibility Difficulties in 
sterilization Low drug loading 
Polymeric micelles Direct or controlled aggregation of block 
copolymers in a solvent, direct dissolution, 
solvent 
evaporation, and dialysis 
Long circulation time, effective EPR, 
Effective for hydrophobic drugs, good 
safety profile,  
Very small size (10-100nm), good leading 
capability, helpful for MDR, Simple 
functionalization for the targeting, easy of 
sterilization 
Difficult polymer synthesis, Not 
good for hydrophilic molecules, In-
vivo instability, Slow extravasation, 
risk of chronic liver toxicity due to 
slow metabolic process 
Dendrimers Convergent and divergent synthesis method of 
chemical polymerization 
Formulation having particle size range 
from 1 to 100 nm, surface 
functionalization is easy due to presence of  
multiple functional groups  
Monotonous preparation techniques 
and toxicity is also concern because 
of reaction solvent. 
Metallic 
nanoparticles/mag
netic nanoparticles 
Chemical reaction (Photoreduction), Laser 
ablation, Sonochemical reactions, Low-
temperature vapour co-
condensation,biological method 
Availability of variety of metallic 
nanoparticle, theranostic carrier, targeting 
is easy due to presence of multivalent 
surface, multiple payload, easy to achieve 
small size even of 5nm, excellent EPR 
Stability and control chemical 
reaction is challenging work, 
toxicity due to reactive surface 
 
368    Current Cancer Drug Targets, 2013, Vol. 13, No. 4 Akhter et al. 
PTX accumulation via WGA-receptor mediated endocytosis 
and IPM-facilitated intracellular drug release. WIT-NP 
cytotoxicity can be ascribed to PTX-induced tumor cell 
apoptosis and cell cycle arrest at G2/M-phase [75]. 
Solid Lipid Nanoparticles (SLN) 
SLNs offer an attractive and efficient means of drug 
delivery, particularly for hydrophobic, poorly water soluble 
drugs. They combine the advantages offered by liposomes, 
NPs and fatty emulsions. SLNs are comparatively stable 
colloidal carrier systems in which the drug is entrapped in a 
lipid core, and manufactured by high-pressure homo- 
genization or microemulsification technique [76]. Significant 
advantages presented by SLNs over polymeric systems are 
their low toxicity due to lipid biodegradability, and small 
size which helps to bypass the RES.  
Inorganic Nanoparticles 
The synthesis of inorganic NPs is an active area of 
application research in nanotechnology. Some common 
metals of utility in anticancer drug delivery include gold 
(Au), copper (Cu), and silver (Ag), and other non-metallic 
inorganic carriers, such as silica. Among these, gold NPs 
have emerged as superior carriers following their excellent 
optical and photoelectric properties, inertness and non-
toxicity, higher stability, ease of preparation, scope for 
bioconjugation and bio-modification with thiol, disulfides 
and amino groups. Their dispersibility can be augmented by 
conjugation with thiolated-PEG [77]. Important areas of gold 
NPs applications are their use as contrasting agents in 
diagnosis, and in photothermal cancer therapy. In recent 
years, gold NPs are most extensively evaluated in oncology 
as compared to the other metallic NPs. Gold NPs have 
unique properties that make them potential candidates in 
therapeutic oncology [78-81]. Gold nanomaterials have 
optical properties with high absorption efficiency 
particularly in the IR region that can easily be enhanced by 
changing the shape and surface area at the nano scale [81]. 
Gold nanomaterials in particular shapes like nano-rods, 
nano-stars, nano-cages and nano-shells show excellent 
localized surface plasmon resonant properties which 
particularly favor their applicability in oncology. The highly 
tunable and multivalent surface of gold NPs favor high 
payload by covalent or non-covalent conjugation [82, 83]. 
Furthermore, it is possible to functionalize the gold NPs for 
active targeting with targeted ligands. For example, PEGylated 
gold NPs have been conjugated with human transferrin (Tf) 
by amine-carboxylate reaction that showed significantly 
improved uptake of particles in cancer cells after i.v. 
administration to mice bearing Neuro2A tumors [84].  
Shen and co-workers demonstrated effects of 
functionalized gold NPs on the binding of dacarbazine to 
DNA bases. They illustrated the apparent enhancement of 
the electrochemical response of dacarbazine revealing the 
facilitation of specific interactions between the drug and 
DNA bases [85]. Cherukuri et al. presented an informative 
review on the emerging role of NPs especially gold in the 
hyperthermic treatment of cancer. Metallic NPs induce 
hyperthermic cytotoxicity when exposed to near-infrared 
radiation or radiofrequency fields [86]. Recently, a couple of 
reviews presented by Akhter et al. [87] and Ahmad et al. 
[88] elaborated the properties and applications of metallic 
NPs in oncology. 
Magnetic Nanoparticles 
The basis behind the formulation of magnetic nano- 
particles (NPs) is the fact that the drug is either encapsulated 
into magnetic micro-/nanosphere or conjugated onto them, or 
implanted as a magnetically-active disc. The drug release to 
the blood stream can be controlled utilizing a powerful 
magnetic field in the target tumor area. Magnetic materials 
receive their magnetic responsiveness to a magnetic field 
from materials like magnetite, iron, nickel, cobalt, 
neodymium-iron-boron, and samarium-cobalt. Ferrofluids 
are liquids which become strongly magnetized in the 
presence of a magnetic field. They are colloidal liquids of 
nanoscale ferromagnetic particles suspended in a carrier fluid 
(organic/aqueous). Iron oxide NPs is the most commonly 
used due to its biodegradable nature, biocompatibility, super- 
paramagnetic effects and ability to serve as a contrast agent 
in MRI. Once compartmentalized within the lysosomes of 
RES cells, they disintegrate to ferritin and/or haemosiderin 
(antiferromagnetic forms of iron) [89]. A water-dispersible 
oleic acid (OA)-pluronic-coated iron oxide magnetic NP 
formulation was developed by Jain et al. and subsequently 
loaded with high doses of water-insoluble anticancer agents. 
This formulation was used as a universal drug carrier system 
for systemic administration of water-insoluble drugs, and 
simultaneously permitting magnetic targeting and/or imaging 
[90]. Yallapu and co-workers have developed a multilayer 
approach for water-dispersible superparamagnetic iron oxide 
nanoparticles (SPIONS) for hyperthermia, MRI and drug 
delivery applications. Iron salts, in the presence of ammonia, 
were precipitated to obtain iron oxide core NPs and coated 
with -cyclodextrin and pluronic polymer. Consequently, the 
formulation was highly water dispersible, enabling entrapment 
of anticancer drugs in -cyclodextrin and pluronic polymer 
coatings for sustained drug release and showed superior 
hyperthermia effects with time under alternating magnetic 
fields as compared to pure magnetic nanoparticles and -
cyclodextrin coated NPs [91]. In yet another study conducted 
by Maeng et al., multifunctional doxorubicin-loaded SPIONS 
for chemotherapy and MRI in liver cancer were developed. 
Polymeric NPs composed of poly(ethylene oxide)-trimellitic 
anhydride chloride-folate, doxorubicin, superparamagnetic 
iron oxide and folate, and exhibited superior anticancer 
activity by targeting folate receptor (FR)-expressing tumors, 
thus enhancing the bioavailability and efficacy of the drug 
[92]. 
Dendrimers 
Dendrimers form an important connecting link between 
molecular chemistry and polymer science [92]. They are 
highly branched, globular, monodisperse, nanoscaled, and 
uniformly distributed three-dimensional polymeric 
macromolecules consisting of three distinct domains: (a) a 
central core containing a single atom/atomic group with at 
least two identical chemical functions, (b) branches 
emanating from the core, comprising of repeating units 
organized in geometric progression resulting in a series of 
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radially concentric layers called “generations”, and (c) 
exteriorly located terminal functional groups. Since they 
possess both hydrophobic and hydrophilic areas, drug 
molecules can be loaded depending upon their solubility 
characteristics. They serve as an ideal targeting and imaging 
agents due to their highly asymmetric shape, multiple 
branching and multivalent tree-like structures. Among 
different dendritic polymers, polyamidoamine (PAMAM) 
dendrimers are the most widely used for chemotherapeutics. 
In the recent past, multifunctional PAMAM dendrimers with 
an imaging agent (fluorescein isothiocyanate) conjugated 
with biotin and folic acid as targeting ligands, and taxol as 
therapeutic agent have been elucidated for parallel use in 
diagnosis and therapy. Conjugation of partially-acetylated 
PAMAM dendrimers with imaging modalities might be  
used for cancer therapy and diagnosis. Enhanced drug 
loading and extended delivery of 5-fluorouracil was 
observed with pegylated PAMAM dendrimers, with few 
blood dyscrasias due to restricted uptake of drug through 
RES [93]. Gardikis et al. developed a liposomal-locked in-
dendrimer (LLD) formed by dipalmitoylphosphatidylcholine-
dipalmitoylphosphatidylglycerol (DPPC-DPPG) lipids and 
poly(amido amine) incorporating the drug doxorubicin. The 
study showed that phase separation between DPPC-DPPG 
lipids and dendrimer promote the stability of liposomal 
membrane and co-operativity of the relevant gel to liquid 
crystal transitions, which is augmented in the presence of 
dendrimers and drug [94]. 
Carbon Nanotubes (CNTs) 
Over the last several years, CNTs have been extensively 
explored in almost every single cancer treatment modality, 
including drug delivery, lymphatic targeted chemotherapy, 
thermal therapy, photodynamic therapy and gene therapy. 
CNTs were first discovered by Iijima in 1991 [95]. They 
belong to the family of fullerenes, i.e. the third major 
allotropic form of carbon after graphite and diamond [96]. 
They are structurally thin sheets of benzene ring carbons 
rolled up uniformly to form a smooth, seamless rod-like 
tubular structure. CNTs can be single-walled (SWNT), 
which essentially consist of a layer of cylinder graphene, or 
multi-walled (MWNT) containing several concentric 
graphene sheets [96]. Some important techniques to produce 
CNTs are laser ablation, electric arc discharge, and thermal 
or plasma-enhanced chemical vapor deposition (CVD) [97, 
98]. Liu et al. synthesized a series of amphiphilic polymers 
by anchoring PEG of different lengths at various densities on 
poly(maleic anhydride-alt-1-octadiene) [PMHC18]. PEG-
PMHC18-coated SWNTs in mice after i.v. injection showed 
ultra-long elimination half-life and significantly higher 
tumor uptake [98]. Chen et al. demonstrated that a higher 
epirubicin loading can be achieved by utilizing carboxylated 
CNTs (cMWNT) [99]. The loading process was mainly 
attributed to - stacking between epirubicin and graphene 
surface of CNTs. Carboxylic acid group also facilitated 
functionalization with the targeting group that PEGylated 
MWNTs penetrated mammalian cells without damaging the 
plasma membrane and selectively accumulated in MDR-
cancer cells as efficiently as in sensitive cancer cells [99]. 
These intracellular translocations of PEGylated MWNTs 
were visualized in MDR-Hep G2-DR and sensitive Hep G2 
cells, as observed by fluorescence and transmission electron 
microscopy. This study, thus gives the strong evidence 
regarding development of PEGylated MWNTs as an 
efficient drug carriers to conjugate drugs for overcoming 
MDR in cancer chemotherapy [99]. 
Quantum Dots (QDs) 
Semiconductor QDs are nanoparticles (2-100 nm) that 
are considered as the potential candidate in traceable drug 
delivery because of their size-tunable absorption bands and 
emission color [100]. Additionally, photoluminescence of 
QDs is outstandingly bright and stable, making them suitable 
alternatives for biomedical imaging and therapeutic 
interventions [101]. Semiconductors from groups II-IV or 
III-V of the periodic table are employed, for example, 
indium arsenide, cadmium telluride, and cadmium selenide. 
Various advantages of QDs over ionizing radiations, 
chemotherapy and radiation therapy are: (a) high quantum 
yield; (b) resistance to chemical modification; (c) intrinsic 
fluorescence emission spectra; and (d) adjustable optical 
properties by regulation of size and composition. 
Photosensitizing QDs produce radicals upon absorption of 
visible light. This approach is limited for superficial tumors. 
Another major drawback to the use of QDs is the poor 
availability of photostable NIR fluorophores and 
photosensitizing drugs [100]. A QD-aptamer-doxorubicin 
conjugate functionalizing the surface of fluorescent QDs 
with A-10 RNA aptamer was developed by Bagalkot et al. 
These QDs were able to differentially uptake and image 
prostate cancer expressing prostate-specific membrane 
antigen [102]. Gao et al. developed multifunctional QD 
probes for simultaneous tumor targeting and imaging. Early 
diagnosis and individual tailorized treatment of oral cancers 
could be achieved by developing NIR QD conjugated with 
cell penetrating peptide and labelling oral squamous 
carcinoma cells with QD conjugates [103]. Li et al. utilized 
PAMAM dendrimers to modify QDs, thereby enhancing 
their water solubility. These dendrimer-modified QDs were 
conjugated with DNA aptamers specifically targeted to U-
251 human glioblastoma [104]. Chen et al. investigated the 
potential of QDs for quantitative estimation of HER2 as a 
micropathologic indicator of tumor size. Usage of QDs has 
led to a better revelation of breast cancer heterogeneity, 
which can, in turn be useful in formulating a more 
personalized and targeted therapy for breast cancer [105]. 
RECENT ADVANCEMENTS AND FUTURE TRENDS 
Attenuation of MDR (Multi-Drug Resistance) 
Resistance against drugs remains the major challenge in 
oncology. Drug resistance can be of non-cellular and cellular 
origin. Poorly vascularized tumor cells/tissues or 
physiological barriers are considered as the cause of non-
cellular drug resistance that significantly diminishes drug 
access to the cancerous sites. Cellular drug resistance can be 
due to over-expression of the drug transport pump (for 
example P-gp efflux transporter), drug-resistance proteins, 
enhancement of the DNA repair capacity and reduction of 
the apoptosis regulation [106]. Amongst the aforementioned 
mechanisms, the role of P-gp is most extensively studied. P-
gp is a 170-kDa transmembrane glycoprotein that functions 
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as an efflux system to remove xenobiotics from inner cell 
environment. Various P-gp inhibitors have been discovered 
to overcome drug resistance (e.g. cyclosporin A, ramipril 
and cuminaldehyde) and among them, some of the P-gp 
inhibitors have shown the restoration of cancerous cell 
sensitivity to cytotoxic agents [106]. 
Alternative strategies against MDR are the development 
of the novel concept of nanotechnology-based drug delivery 
systems, which selectively target the tumor-site (cellular or 
tissue targeting) through selective endocytosis or passive 
diffusion leading to by-pass the P-gp efflux [6], for example, 
doxorubicin-loaded poly-(alkyl cyanoacrylate) NPs [107], 
metallic doxorubicin-loaded particles, PACA NPs [108] and 
nanoparticulate conjugate of 20 (S)-camptothecin [109]. 
Schluep et al. have shown the ability of such particles to 
overcome drug resistance [109]. In clinical studies, 
liposome-loaded doxorubicin was able to overcome drug 
resistance in AIDS-related Kaposi's sarcoma [110]. 
Furthermore, NPs such as polymeric micelles and polymeric 
conjugates as a drug delivery carrier showed promising 
results in patient who had previously failed to chemotherapy 
[110-112]. Ligand-based strategies, particularly receptor 
targeting, have also been applied to overcome MDR since 
they are able to interact with the receptor and internalized 
through receptor-mediated endocytosis. For example folate-
targeted DOX-nanoparticles and transferring-conjugated 
paclitaxel NPs exhibited greater cytotoxicity than their free 
counterpart in MDR model [10]. 
Nanotechnology in Cancer Theranostics 
Diagnosis and therapy combined in one system is the 
current advanced biomedical tool referred to as theranostics 
[87]. The primary goal of theranostics is to selectively target 
the disease confined to tissue/cell in order to increase 
diagnostic and therapeutic selectivity that makes the 
treatment shorter, safer, effective and inexpensive. 
Biocompatible/biodegradable nanocarriers are currently 
under development in oncological theranostics that would 
enable precise diagnosis and therapy. Lukianova-Hleb et al. 
have studied the light-based generation and detection of 
plasmonic gold NPs in living cells, with focus on tailoring 
the plasmonic NP properties in one cell and evaluating the 
multifunctionality of the nanoparticle [113]. Recently, 
numerous published reports discussed the design, 
physiochemical characteristics and applications of magnetic 
nanoparticles. These NPs can act both an imaging agent 
(diagnosis) and a drug carrier (therapy) [114]. Shim et al. 
coated RNA-encapsulated polyplexes, covalently bonded 
with gold nanoparticle through an acid labile linkage to 
explore theranostic use (optical imaging and gene silencing) 
[115]. The different possible characteristics like imaging 
property, drug carrying and targeting capacity with long 
circulating behavior (shown with PEG) are given in Fig. (2). 
The multifunctionality associated with NPs includes 
imaging (single or dual modality), therapy (single or mutiple 
drugs) and targeting (uni- or multi-liganded). Although there 
are certain unanswered questions and challenges remaining 
for the establishment of NPs in clinical applications, 
extensive clinical data are needed, with progressive and 
clinical-centric efforts to overcome these queries and 
obstructions that will certainly lead to rational design of 
nanoparticles, possessing improved selectivity and efficacy. 
Current knowledge regarding the safety of NPs is in its 
infancy. The pharmacokinetic parameters and their outcome 
need a comprehensive exploration and generation of 
databases for health-risk particularly associated with vital 
organs need to be created. In the next few years, many 
applications of nanotechnology will be put to clinical 
practice. Table 3 summarizes the selected examples of 
nanomedicines which are approved by the FDA or are in 
some phase of clinical trial for cancer therapy. 
TOXICITY ISSUES 
Apart from immense importance of nanomaterials in 
cancer imaging and therapy, its toxic effects are also a major 
concern especially after chronic administration. Different 
polymers have different toxicities, like complement 
activation, carcinogenicity, teratogenicity, and immuno- 
genicity [116, 117]. Thus choosing safe polymers for the 
design of NPs is itself a major hurdle. Careful evaluation of 
 
Fig. (2). Illustrative image defining the different characteristics of multifunctional nanomedicine such as imaging property, drug carrying and 
targeting capacity with long circulating behavior. 
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the potential toxicity of residual solvents, polymers and the 
developed particles is critically important. Presently, non-
toxic and biodegradable ingredients are used to design NPs 
due to which carrier-associated toxicities tend to be mild. 
However, NPs accumulates in the liver, spleen, and bone 
marrow leading to increased toxicities to these organs. Many 
studies have identified liver as the primary organ responsible  
for reticuloendothelial capture of NPs, often due to 
phagocytosis by Kupffer cells. Hepatotoxicity has been 
observed in mice treated orally with nano-zinc particles 
[118]. Similarly, i.v. administration of cationic PAMAM 
dendrimers to mice has been observed to cause liver injury 
[119]. There are also safety concerns with particular NPs that 
are capable of crossing the BBB. For example clinical trial 
of an HPMA-conjugated paclitaxel had been terminated due 
to neurotoxicity [120]. Among the nanomedicines, metallic 
nano-carriers have been extensively evaluated for their 
toxicity and interaction with biological systems [121]. 
Depending on the nature and type of metallic nanoparticles 
[MNPs], different grades of toxicity have been reported at 
Table. 3. Nanomedicine as cancer therapeutics/imaging agents under different stages of development. 
NANOMEDICINES DRUG APPLICATION STATUS REFERENCE/COMPANY 
Paclitaxel Malignant pleural effusions Phase I NeoPharm, USA 
CPX-1 (Liposomal irinotecan) Colorectal cancer Phase II Celator Pharmaceuticals 
INGN-401 Metastatic lung cancer phase I Introgen Therapeutics Inc, USA 
SPI-77(stealth liposome cisplatin) Lung cancer Phase III ALZA pharmaceuticals, USA 
Cytosine arabinoside Neoplasic meningitis Phase IV ALZA pharmaceuticals, USA 
Daunorubicin citrate Kaposi's sarcoma FDA approved Gilead Sciences, Inc.USA 
Doxorubicin Ovarian cancer FDA approved ALZA pharmaceuticals, USA 
PEGylated liposome/doxorubicin 
hydrochloride 
Ovarian cancer ” Ortho Biotech 
Gentuzumab ozogamicin Acute myeloid leukemia FDA approved Wyeth-Ayerst, USA 
Vincristine sulfate Acute lymphoblastic leukemia FDA approved Hana Biosciences, Inc, USA 
LIPOSOMES 
OSI-211 (Liposomal lurtotecan) Various cancer Phase II OSI Pharmaceuticals 
MRX-952 Anticancer Preclinial ImaRx Therapeutics, USA POLYMERIC 
MICELLES Carmustine Glioblastoma multiforme FDA approved Guilford Pharm.Inc. USA 
SOLID-LIPID 
NANOPARTICLES 
Paclitaxel-taxol Mammary cancer (metastatic) FDA approved American Pharm.Partner/Amer. 
BioScience, USA 
Copolymer of N-(2-hydroxypropyl) 
metacrylamide/camptothecin 
Various cancer Phase I Pharmacia, USA 
POLYMERIC 
NANOPARTICLES 
 NK-105 (PEG-polyaspartate) 
nanoparticle of cisplatin 
Various cancer Phase II Nippon Kayaku Co. Ltd. 
Combidex Tumor imaging Phase III Advanced Magnetics, USA 
Resovist® (Iron oxide nanoparticles 
coated with carboxydextran) 
Tumor imaging In European 
market  
Bayer Schering Pharma AG 
IRON OXIDE 
NANOPARTICLES 
Feridex® (Iron oxide nanoparticles 
coated with dextran) 
Tumor imaging FDA approved Berlex Laboratories 
ALBUMIN 
NANOPARTICLES 
Albumin bond nanoparticle (Abraxane) Mammary cancer (metastatic) FDA approved American Pharm.Partner/ 
Amer.BioScience, USA 
CYCLODEXTRIN 
NANOPARTICLES 
Cyclosert-camptothecin Metastatic solid tumors IND filed Insert Therapeutics, USA 
Verigene  Diagnostics Market Nanosphere, USA GOLD 
NANOPARTICLES Aurimune (Colloidal gold/TNF) Solid tumors Phase II CytImmune Science 
SILICA 
NANOPARTICLES 
AuroLase (Gold coated silica 
nanoparticles) 
Head and neck cancer Phase I Nanospectra bioscience 
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organ, tissue, cellular and sub-cellular level due to their 
physiochemical properties (viz. size, shape, electrical charge 
on the surface, chemical composition, surface structure 
(surface reactivity, surface group, inorganic or organic 
coatings), solubility and aggregation behavior) [122-124]. 
The mechanisms of toxicity induced by MNPs are a 
combination of different events such as direct destruction of 
cellular component like DNA, RNA and cellular proteins 
due to free radical generation. Moreover, increased oxidative 
stress plays a key role as well [125]. Recently, it was found 
that ‘naked’ CdTe quantum dots cause damage to lipid 
membranes of mitochondria and nuclear structures [125]. 
Destruction of plasma membrane by metallic NPs was 
supported by the work of Sayes et al. on Cobalt (
60
Co) NPs 
[126]. Metallic NPs influence the reproductive organs as it 
was found that particles may reduce spermatogonial cell 
proliferation [127-130]. Free radical generation and 
induction of inflammatory mediators is considered pivotal 
for such effects [131]. Apart from the male reproductive 
organ, Browning et al. reported the effect of metallic NPs 
over female reproductive system in animal experiments 
[132]. They confirmed that gold NPs can diffuse into the 
embryo and lead to teratogenic deformities [133]. Increased 
surface activity due to reduction in particle size (increase in 
surface area:volume ratio) influences the interaction of 
metallic NPs to the biological system [87]. The correlation 
between the size and toxicity is corroborated by the report of  
De and co-workers that illustrated that colloidal gold NPs 
with small size (10-50 nm) cause more toxicity in 
comparison to the larger particles (100-200 nm) [134]. 
Moreover, Chen et al. studied the oral toxicity of copper NPs 
and found that their LD50 increased sharply with the decrease 
in particle size [135]. In another report, it was demonstrated 
that gold NPs with the size ranging from 2.8 to 38 nm  
were more toxic and induced immunological reactions [136]. 
Size-dependent adverse effects of silver NPs were found  
in in-vitro studies on hepatocytes indicating decreased 
mitochondrial function, lactate dehydrogenase (LDG) 
leakage and abnormal cell morphologies [137]. Influence of 
surface charge on the metallic NPs has also been addressed 
in the literature. Recently, dose-dependent effect on viability 
and capacity of nerve cells was seen in case of anionic 
MNPs [138]. Although in vivo findings on MNPs toxicity 
have also been reported, but majority of the data on the 
toxicity of MNPs have been the outcome of in vitro testing. 
It is promising that various efforts are being undertaken for 
reducing the uptake of NPs by macrophages (MPs) and to 
increase their accumulation at the active site through surface 
modification and/or incorporation of targeting ligands to the 
polymers/NPs [139-141]. On the basis of reports, the toxic 
Fig. (3). Simplified pictorial diagram representing the possible toxic effects of nanomedicines on different body organs. 
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effects of nanomedicines on different body organs are 
exemplified in Fig. (3). In nanomedicine formulation 
development, PEGylation is the most common technique 
used to make long circulating nano-carriers. Moreover, 
plenty of published papers on this subject indicate that such 
hydrophilic polymer coating reduces the nanoparticles-
associated toxicity. Regardless of the prevalent use of 
PEGylation for prolonging the circulation of nanomedicines, 
its mechanism for such action and interaction with biological 
system in the systemic circulation is not entirely clear. In 
fact, PEG has been shown to form a brush border over the 
nanomedicines’ surface that leads to non-specific 
impermeable hindrances and sterically prevents access of 
tissue proteins [142]. Chain length, density, conformational 
freedom and flexibility of PEG are critical in making the 
nanomedicine-surface free from cellular interaction [143]. 
Although, such kind of coating provides non-specific 
shielding, but it was found that in case of PEGylated 
hexadecyl cyanoacrylate NPs, PEG was able to reduce the 
adsorption of ApoC and immunoglobulins, but not the other 
plasma proteins [144]. Similarly, with uncharged liposomes 
(made up of phosphatidylcholine and cholesterol) and 
negatively charged liposomes (made up of phosphatidic 
acid), coating with PEG-DSPE 2000 does not provide 
shielding from plasma protein adsorption [145]. Recently, 
several reports have been published that indicate the rapid 
clearance of PEGylated liposomes [146]. This effect is 
attributed to the formation of PEG-specific antibodies that 
prompt complement absorption [145]. Therefore, it should be 
noted that expression of specific antibodies to the particles or 
coating material may affect the pharmacokinetics, efficacy 
and safety of nanomedicines. 
Toxicity Assessment 
In Vitro Cells and Gene-Based Toxicity 
To generate information on toxicity, studies at different 
levels (in vitro, in vivo and biochemical) must be carried out. 
Although in vitro studies may overcome the complexity of 
animal-based experiments, they may oversimplify processes 
and lack in vitro-in vivo correlation. However, they allow for 
a level of control well-suited for elucidating toxic effects and 
their mechanism at molecular level, which is extremely 
difficult to interpret in in-vivo studies. A gene-based 
approach (DNA strand breaks, chromosome damages and 
gene mutation, etc.) has the advantage of assessing toxicity 
at low-dose level and may detect carcinogenic effects which 
may not be monitored via classical cytotoxicity studies. The 
nature and mechanism of interaction between NPs, and 
molecular and cellular targets can be elucidated by TEM, 
SEM or X-ray-based microscopy.  
Oxidative Stress and Reactive Oxygen Species (ROS) 
Assessment 
Reduction of size to nano-scale leads to the conversion of 
normal particles to highly-active charged particles, which on 
interaction with cellular components and biological 
processes generate ROS, and produce oxidant injury. This 
paradigm may be used to evaluate the toxic potential of NPs 
[87]. Oxidative stress occurs when ROS production exceeds 
the defense capacity of the system and in such circumstances 
leads to damage of biomolecules like lipids, DNA, RNA, and 
proteins, resulting in excessive cell proliferation, apoptosis, 
and mutations. Metallic and inorganic NPs are known to 
induce oxidative stress through ROS generation during redox 
reaction by interruption of the electronic flux, perturbation of 
the permeability transition, and diminution of protective 
cellular component like glutathione [146-148]. ROS 
production can be monitored through ESR or with the use of 
fluorescent spectroscopy with or without quenchers such as 
furfuryl alcohol and superoxide dismutase. Furthermore, 
within a living cell this activity can be monitored through 
fluorescent microscopy or confocal microscopy. In addition, 
change in intracellular free calcium, mitochondrial function 
and structural integrity also serves as a tool to study ROS 
production and their associated oxidative stress. 
REGULATORY ASPECTS  
The positive impact of nanomedicines on the quality of 
life in life-threatening diseases like cancer is evident in 
clinical trials. However, applying these initial outcomes to 
clinical practice still needs to be rationalized and carefully 
controlled in terms of risk-to-benefit ratio, and is carefully 
overseen by regulatory authorities such as FDA, MHRA and 
EMEA. For any such products, the agencies have to set 
protocols that basically work for the assessment of three 
parameters: quality, safety and efficacy. The first generation 
of nanomedicines is already in clinical practice and some of 
it is now in the phase of generic development. Both generic 
manufacturers and regulatory agencies are struggling to 
finalize the studies that are required to demonstrate the bio-
equivalency of nanometric generic medicines compared to 
innovator products. This has been clearly demonstrated with 
several unproductive efforts in the generic development of 
nab-paclitaxel formulation. The claimed bio-similar of nab-
paclitaxel, when evaluated, did not fit to reproduce particle 
size, stability, potency and other physicochemical attributes 
of nab-paclitaxel [149]. Moreover, unlike nab-paclitaxel, the 
reconstituted nanomedicine exhibited poor stability when 
evaluated for accelerated stability testing i.e. it formed 
aggregates within 24 h of study period. Pharmaceutical or 
chemical equivalence and/or bioequivalence may not 
sufficiently indicate the function of nanomedicines at the site 
of action, as assumed for standard conventional preparations. 
In addition, several liposomal formulations containing 
amphotericin B and doxorubicin have recently gone off-
patent. The lack of critical information regarding composition, 
dimensional configuration of components and critical 
parameters that are essential for optimal performance of 
nanomedicines, raise concern about “generics” that may be 
approved based on conventional drug product standard and 
the guidelines but without having the same quality of the 
innovator. This exemplifies that how generic nanomedicine 
manufacturers and regulatory authorities are going to face 
challenges in the development and approval of such 
products. So, it is crucial that a comprehensive physico- 
chemical based understanding of nanomedicines and 
recognition of critical parameters that affect their functioning 
be conducted early in developmental that will help 
regulatory bodies and industry in framing quality standard of 
nanomedicines products. Indeed, FDA has recently begun to 
consider relevant approval standards for generic copies of 
nanomedicines. A recently issued guideline in case of 
374    Current Cancer Drug Targets, 2013, Vol. 13, No. 4 Akhter et al. 
doxorubicin-loaded liposomal formulation (Doxil
®
) is an 
example for the generic development. Current scenarios 
illustrate that nanomedicines have defined their physico- 
chemical characteristics but lack suitable pharmacokinetic 
models for such medicines. Considerations such as patho- 
physiology, target tissue, biodistribution and elimination, 
impact of their size and surface characteristics on organ, 
tissue and cellular localization, and better understanding  
of pharmacokinetics and pharmacodynamics correlations 
need to be addressed in experimental models. Moreover, 
quantitative techniques need to use for biodistribution 
studies of polymers and metals. In the context of polymeric 
and metallic nanomedicine therapeutics, carrier systems are 
developed with newer complex architectures (for example, 
dendrimers, quantum dots, SPIONs and multifunctional gold 
nanomaterials, etc.) and such carrier systems may be given 
by different route, viz pulmonary, i.v. and organ-directed 
injections. With the increased complexity of the architecture, 
induction of multifunctionality in a single carrier system 
frequently falls into a gap between medicines and medical 
devices regulation. It is to be noted that biological and 
medical devices assessment guidelines are based on general 
and non-specific standards. Moreover, a regulatory guideline 
addressing new nanometric devices and different category of 
medicines harmonized for the global regulatory will be 
highly productive.  
CONCLUSION 
In the current multidisciplinary arena, nanotechnology is 
in a distinctive status to transform cancer chemotherapy and 
diagnosis to produce a new generation of cancer 
therapeutics/theranostics (categorized as nanomedicines) 
with high sensitivity and precision for cancerous cells 
leading to reduction of the conventional therapeutics-
associated predictable toxicity. There are an increased 
number of FDA-approved cancer nanomedicines, their 
socio-environmental impact need to be addressed. While 
establishing the nanomedicines in clinical oncology practice, 
some key points need to be considered; toxicological data 
review of nanomedicines prior to use, in vivo-in vitro 
toxicity testing to understand the toxicity of new 
nanomedicines and its environmental impact. 
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